Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03925324
Other study ID # STEMVAD-001
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date May 3, 2019
Est. completion date August 16, 2021

Study information

Verified date January 2022
Source Medstar Health Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A study to assess the safety and preliminary efficacy of serial intravenous dose of Allogeneic Mesenchymal Bone Marrow Cells in subjects with heart failure and implanted left ventricular assist devices.


Description:

A double-blind, placebo-controlled, single-center, randomized study to assess the safety and preliminary efficacy of a three serial intravenous doses of allogeneic mesenchymal bone marrow cells to subjects with heart failure and implanted left ventricular assist devices.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date August 16, 2021
Est. primary completion date August 16, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age =18 years. 2. Advanced Heart Failure 3. Advanced HF defined as HF requiring LVAD implantation and deemed stable on his/her LVAD. 4. On stable medical therapy (per the discretion of the treating physician) including beta-blockers, ACE-inhibitors, angiotensin receptors blockers, angiotensin receptor neprilysin inhibitor, mineralocorticoid receptor antagonists, isosorbide, hydralazine, and mineralocorticoid receptor antagonists) and optimized pump speed for at least a month prior to randomization. 5. HS-CRP level=2 mg/l. 6. NYHA class II-III symptoms. 7. Ability to understand and provide signed informed consent. 8. Reasonable expectation that patient will receive standard post-treatment care and attend all scheduled safety follow-up visits Exclusion Criteria: 1. Women of childbearing potential. Postmenopausal women or women with permanent contraception method (defined as total hysterectomy) will not be excluded. 2. History of debilitating stroke (modified Rankin Score > 3) within 3 months. 3. The likelihood of requirement of cardiac surgery during the study period. 4. Presence of clinically significant, uncorrected left sided valvular heart disease, active acute myocarditis, or uncontrolled hypertension defined as Persistently elevated mean arterial blood pressure (>100 mmHg). Echocardiography within 12 months of screening. Patients can be re-evaluated, at the discretion of the investigator. 5. QTc >550 ms (in the absence of bundle branch block, interventricular conduction delay or ventricular pacing). Electrocardiogram (ECG) within 60 days. 6. History of cardiac arrest within 3 months. 7. Hypertrophic or infiltrative cardiomyopathy. 8. Considered or listed for organ transplantation or history of organ transplantation 9. Illness other than HF with life expectancy less than 12 months. 10. Enrolled in an interventional trial or received an experimental drug or device within 30 days of randomization. 11. Left ventricular assist device implantation >2 years prior to enrollment. 12. Biventricular assist device (Bi-VAD) support. 13. Severe COPD defined by FEV1<1L, FEV1/FVC<70% within 12 months if known history of COPD, otherwise FEV1<1L, FEV1/FVC<70% within 24 months 14. Uncontrolled seizure disorder. 15. Clinically significant hematologic, hepatic, or renal impairment as determined by screening clinical laboratory tests within the last 30 days: Liver disease = ALT or AST > 3x normal, alkaline phosphatase or bilirubin >2x normal Renal disease = on long term dialysis Hematologic = Unexplained persistent leukocytosis (WBC >11 K/UL) or hemoglobin < 8.5 gm/dl 16. Presence of any other clinically-significant medical condition, psychiatric condition, or laboratory abnormality, that in the judgment of the investigator or sponsor may affect compliance with the study protocol or pose a safety risk to the subject. 17. Inability to comply with the conditions of the protocol. 18. Acute coronary syndrome within 4 weeks (clinical diagnosis, confirmed by electrocardiographic abnormalities and elevation of troponin-I). 19. Malignancy within the previous five years, except adequately treated basal cell carcinoma, provided that it is neither infiltrating nor sclerosing, and carcinoma in situ of the cervix. 20. Active uncontrolled systemic infection. Positive blood or deep tissue cultures or clinical or imaging evidence of systemic infection despite complete course of effective antimicrobial therapy as determined by infectious diseases. Localized (non-systemic) infection is not an exclusion criterion. Patients can be re-evaluated, at the discretion of the investigator. 21. Early postpartum cardiomyopathy (within six months of diagnosis). 22. Presence of inherited or acquired immune deficiency or human immunodeficiency virus infection (HIV). Negative HIV test within the preceding 12 months is required. 23. Systemic corticosteroids, immunosuppressive drug therapy (cyclophosphamide, methotrexate, cyclosporine, tacrolimus, azathioprine, mycophenolate, sirolimus, etc.), and DNA depleting or cytotoxic drugs taken within four weeks prior to study treatment. 24. Known Porphyria. 25. Allergy to sodium citrate or any caine type of local anesthetic. 26. Patient enrolled in hospice care.

Study Design


Intervention

Biological:
Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)
Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg
Other:
Placebo
1.5 mL/kg Lactated Ringer's Solution

Locations

Country Name City State
United States MedStar Washington Hospital Center Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Medstar Health Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Temperature Temperature up to 12 months post enrollment
Primary Uncontrolled Systemic Infection Number of admission for uncontrolled systemic infection up to 12 months post enrollment
Primary All-cause Mortality Rate of Death up to 12 months post enrollment
Secondary NK Cell Depletion percent reduction in NK cells Baseline to day 90
Secondary Change in the Following Cardiac Biomarker The change in the lab values N-Terminal Prohormone of Brain Natriuretic Peptide (NT-ProBNP) Baseline and day 90 post initial infusion
Secondary Change in RV Systolic Function Change in RV systolic function Baseline and day 90 post initial infusion
Secondary Hospitalizations Due to Right Heart Failure Number of hospitalizations for to right heart failure day 90
Secondary 6 Minute Walk Distance Changes 6 minute walk distance changes Baseline and day 90 post initial infusion
Secondary Gout Flares Count of gout flares Day 90
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Active, not recruiting NCT04562805 - Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT) N/A
Recruiting NCT05292079 - CAPTURER PMCF Study ( rEPIC04D )
Recruiting NCT05292014 - ANGIOLITE PMCF Study ( rEPIC04F )
Recruiting NCT05292118 - Navitian PMCF Study ( rEPIC04C )
Recruiting NCT05292092 - Essential Pro PMCF Study ( rEPIC04E )
Completed NCT05292105 - NC Xperience PMCF Study( rEPIC04B)
Completed NCT03076801 - Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease? N/A
Not yet recruiting NCT04153383 - Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery
Recruiting NCT02982434 - The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation Phase 2
Recruiting NCT02729064 - Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose Phase 1
Completed NCT02468401 - Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions N/A
Completed NCT02759406 - Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study N/A
Recruiting NCT01681381 - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization N/A
Completed NCT01604213 - Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease Phase 4
Completed NCT01699802 - Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa) N/A
Completed NCT01334268 - RESOLUTE China RCT N/A
Completed NCT01724567 - Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training N/A
Completed NCT02159235 - Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD) N/A